
Merck beats second-quarter revenue estimates and hikes outlook, but cuts profit guidance
Merck beat second-quarter revenue estimates with $16.61 billion and raised its 2026 revenue outlook, but cut profit guidance due to charges from its Terns Pharmaceuticals and Cidara Therapeutics acquisitions.













